

Date: July 26, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of change in time of conference call scheduled on July 26, 2024 in relation to acquisition of 100% stake in Bharat Serums and Vaccines Limited

Reference: Our letter dated July 25, 2024 under subject “Intimation of conference call in relation to acquisition of 100% stake in Bharat Serums and Vaccines Limited”

In continuation to our above-referenced letter dated July 25, 2024, we hereby inform you that a conference call regarding acquisition of 100% stake in Bharat Serums and Vaccines Limited scheduled today i.e. July 26, 2024 will begin at 05:00 p.m. (IST) instead of 04:00 p.m. (IST).

Updated details of the Conference Call are enclosed herewith.

The same are also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh

Company Secretary and Compliance Officer

Encl.: As above



Mankind Pharma Limited
Investors / Analyst Call

You are cordially invited to the conference call,
Scheduled on **Friday, 26th July 2024, at 05:00 pm IST,**
To discuss acquisition of Bharat Serums and Vaccines Limited:

The details of the call are as below:

Conference Call Details	
Date	Friday, 26 th July 2024
Time	05:00 pm - 06:00 pm, IST
Universal Dial-in	+91 22 6280 1102 +91 22 7115 8003
International Toll-Free Numbers	USA : 18667462133 UK : 08081011573 Singapore : 8001012045 Hong Kong : 800964448
Pre-register to avoid wait time	Click here to pre-register for the call and dial in directly without waiting for the operator.

Management will be represented by:

- Mr. Rajeev Juneja – Vice Chairman & Managing Director
- Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
- Mr. Arjun Juneja - Chief Operating Officer
- Mr. Ashutosh Dhawan – Chief Financial Officer
- Mr. Prakash Agarwal – President (Strategy)
- Mr. Abhishek Agarwal – Head - Investor Relations & AVP - Strategy

For details, please contact:

Mankind Pharma Limited Abhishek Agarwal E: investor.relations@mankindpharma.com , T: 011 – 46846700	Adfactors PR Snighter Albuquerque / Smit Shah E: snighter.albuquerque@adfactorspr.com / smit.shah@adfactorspr.com , M: +91 9870789596
--	--